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Introduction: Human multipotent stromal cells (MSCs) isolated from bone marrow or other tissue sources have
great potential to treat a wide range of injuries and disorders in the field of regenerative medicine and tissue
engineering. In particular, MSCs have inherent characteristics to suppress the immune system and are being studied
in clinical studies to prevent graft-versus-host disease. MSCs can be expanded in vitro and have potential for
differentiation into multiple cell lineages. However, the impact of cell passaging on gene expression and function
of the cells has not been determined.
Methods: Commercially available human MSCs derived from bone marrow from six different donors, grown under
identical culture conditions and harvested at cell passages 3, 5, and 7, were analyzed with gene-expression profiling
by using microarray technology.
Results: The phenotype of these cells did not change as reported previously; however, a statistical analysis revealed
a set of 78 significant genes that were distinguishable in expression between passages 3 and 7. None of these
significant genes corresponded to the markers established by the International Society for Cellular Therapy (ISCT)
for MSC identification. When the significant gene lists were analyzed through pathway analysis, these genes were
involved in the top-scoring networks of cellular growth and proliferation and cellular development. A meta-analysis
of the literature for significant genes revealed that the MSCs seem to be undergoing differentiation into a senescent
cell type when cultured extensively. Consistent with the differences in gene expression at passage 3 and 7, MSCs
exhibited a significantly greater potential for cell division at passage 3 in comparison to passage 7.
Conclusions: Our results identified specific gene markers that distinguish aging MSCs grown in cell culture.
Confirmatory studies are needed to correlate these molecular markers with biologic attributes that may facilitate
the development of assays to test the quality of MSCs before clinical use.Introduction
Multipotent stromal cells, also defined as mesenchymal
stem cells (MSCs), undergo sustained growth in vitro
and can give rise to cells of multiple lineages, such as
adipocytes, chondrocytes, and osteoblasts [1-3]. MSC-
based therapies hold potential in the field of regenerative
medicine by combining elements of tissue engineering
and immunosuppression to treat indications of human
disorders, such as organ failure, traumatic limb injuries,
genetic disorders, graft-versus-host disease, cardiovascular* Correspondence: raj.puri@fda.hhs.gov
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als are actively recruiting patients with specific ailments to
investigate the safety and efficacy of MSCs [4,5].
MSCs can be isolated from a number of different tis-
sues, including adipose, dermis, skeletal muscle, men-
strual blood, and umbilical cord blood, but are most
notably derived from bone marrow [6-12]. According to
a consensus of the International Society of Cellular
Therapy (ISCT), MSCs have been classified by the com-
mon characteristics of (a) adherence to plastic in stand-
ard cell-culture conditions; (b) combination of positive
and negative expression of cell-surface markers (CD105+,
CD73+, CD90+, CD45-, CD34-, CD14-, CD11b-, CD79α-,
CD19-, and HLA-DR); and (c) In vitro differentiation intoLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Donor characteristics and cell passage
Number Donor Sex Age Passages Company
1 PCBM1641 M 23 3, 5, 7 ALLCELLS
2 PCBM1632 F 24 3, 5, 7 ALLCELLS
3 167696 F 22 3, 5, 7 Lonza
4 110877 M 22 3, 5, 7 Lonza
5 8F3560 F 24 3, 5, 7 Lonza
6 PCBM1662 F 31 3, 5, 7 ALLCELLS
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trated by cell-culture staining [13]. Classification of MSCs
has been further explored in the areas of additional phe-
notypic expression markers (CD29+, CD166+, CD133-),
the benefits of immunomodulation, and precursory dif-
ferentiation of cells along the ectoderm and endoderm
lineage, as well as their isolation from different tissue
sources [14-19].
As a heterogeneous population, MSCs have made
product characterization a challenging task for investiga-
tors. The heterogeneous population of MSCs is most
likely the result of contaminating cells because of the
variability in isolation methods and culturing proce-
dures, which can greatly influence their phenotype. At-
tempts have been made to reduce heterogeneity through
separation of cells by adhesion characteristics, flow cy-
tometry, or immunomagnetic separation [20-22]. Several
studies have found that MSCs isolated from different tis-
sue sources, including bone marrow, adipose tissue, and
umbilical cord blood, have varying gene-expression pro-
files, which results in different trilineage cell-differentiated
outcomes [23-25]. Furthermore, variation in the behavior
of MSCs isolated from the same tissue sources are ob-
served for different donors [26-30].
For some cell applications, MSC passaging and expan-
sion in cell culture is necessary to generate sufficient
numbers for transplantation. It is not clear what impact
extensive cellular passaging and expansion have on the
biologic activity of MSCs and in their clinical use. It has
been reported that MSC populations become more ho-
mogeneous with serial passaging; however, this leads to
senescent cell behavior and an impaired capacity for
multipotent differentiation [31,32]. Additionally, increa-
ses in cell size and telomere shortening are commonly
associated with aging cells in culture [33-36]. Other var-
iables such as the donors’ age, body mass, gender, en-
vironment, and medical history may have a profound
impact on a population of MSCs for a given therapeutic
use [37,38]. These confounding variables indicate the ne-
cessity of markers that aid in rapid prediction of MSC
quality and safety for a desired function. The present
work aims to identify potentially predictive gene markers
of human bone marrow-derived MSCs indicating cell
aging through two-color gene-expression microarray
technology. We hypothesize that specific gene markers
exist that will distinguish aging MSCs grown in cell
culture.
Methods
Cultivation and expansion of human bone marrow-
derived MSCs
Human MSCs from six different donors were purchased
from ALLCELLS and Lonza (Table 1). Because these
cells were commercially available, no patient consent orapproval from the FDA Research Involving Human Sub-
ject Committee was needed. Flow-cytometry analysis
provided from each company revealed a marker profile
of CD29+, CD44+, CD105+, CD166+, CD14-, CD34-,
and CD45- for each donors’ MSCs. Cell viability was
greater than 85% for all donors. MSCs were cultured in
expansion medium containing αMEM (alpha minimum
essential media) (Life Technologies, Grand Island, NY),
10% FBS (fetal bovine serum) (JM Bioscience, San Diego,
CA), 1% L-glutamine (Life Technologies), and 1% penicillin
G and streptomycin (Life Technologies) under a humidified
atmosphere of 5% CO2 at 37°C, according to Lo Surdo
et al. [39]. After reaching 80% confluence, cells were de-
tached from the flask by using 0.25% trypsin/1 mM EDTA
solution (Life Technologies) and replated at a density of 60
cells/cm2. The cells were expanded until the end of the sev-
enth passage and snap frozen after passages 3, 5, and 7.
Sample preparation: RNA isolation
Total RNA isolation was performed for the six donors at
passages 3, 5, and 7 (18 different samples) by using the
Qiagen RNeasy Mini Kit as per the manufacturer’s in-
structions. RNA quality was analyzed with the Agilent
2100 bioanalyzer if the average RNA integrity value
(RIN) was 9.9 ± 0.16. The RNA concentration was mea-
sured by using the Nanodrop 1000 spectrophotometer.
Microarray hybridization
Microarrays were produced containing 35,035 70-mer
oligonucleotide probes that represented 25,100 unique
genes and 37,632 transcripts, as previously described
[40]. All slides were produced in our laboratory and
quality tested.
Total RNA from each donor at each passage (5 μg)
was reverse transcribed to the corresponding cDNA, as
previously described [41]. The reference material for the
arrays was composed of equal quantities of reverse-
transcribed passage 3 RNA from donors 1 through 6.
Sample cDNA and reference materials were labeled
with Hyper5 and Cy3 reactive dye (GE Healthcare,
Piscataway, NJ), respectively, in 0.1 M sodium bicarbon-
ate, pH 9.1, in the dark for 1.5 hours. After purification by
MinElute column, Hyper5- and Cy3-labeled cDNA were
combined and mixed with the hybridization solution
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solution was pipetted over the entire surface of the slide
and hybridized overnight (16 hours) at 42°C with the Maui
hybridization system. Slides were washed for 4 minutes in
both buffers 1 (1× SSC (Life Technologies) with 0.1% SDS
(Sigma-Aldrich, St. Louis, MO)) and 2 (0.1× SSC), and
then dried for 2 minutes during centrifugation. Samples
from each donor at each passage were run in triplicate in
a randomized block design to reduce possible nuisance
factors (Figure 1A).Figure 1 Global microarray analysis of gene expression. (A) Unsupervi
and 3 for each microarray for the six donors cultured to passage 7, run in t
triangle) represents one sample on one microarray containing 35,035 prob
passage replicates. (C) Box-plot distributions of the technical variability perData acquisition and analysis
Microarray images were collected by using the 4000B
GenePix Axon Scanner (Axon Instruments Inc., Union
City, CA). Slides were scanned at 532 nm for Cy3 and
635 nm for Hyper5 with an image resolution of 5 μm.
Spots were annotated by aligning them to the gene-array
list (Gal file) that was generated according to the print-
ing orientation, and the data were acquired by GenePix
Pro. ArrayTrack software was used to normalized data
by using linear and Lowess methods by using thesed three-dimensional representations of principal components 1, 2,
riplicate, for a total of 54 microarrays. Each symbol (circle, diamond,
es. (B) Kernel density plots of normalized data for each of the donor/
probe for each donor/passage.
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used to perform all calculations and statistical analyses,
including principal component analysis, hierarchic clus-
tering, box plots, and the repeated measures analysis of
variance (ANOVA) models. Microarray data files have
been uploaded into the public repository Gene Expres-
sion Omnibus (GSE56362).
All 34,555 probes, excluding controls, were initially fil-
tered by the technical and biologic variability and the
magnitude of their expression level, as determined by
the A signal (Log2(Cy3 × Hyper5)
1/2). In the technical-
variability filtering step, the standard deviation of the
gene-expression ratio, Log2(Hyper5/Cy3), was calculated
between technical replicates of identical donors/passages
for each probe. The median technical variability per probe
was calculated by taking the median of the 18 (six donors
at three passages each) individual standard deviations.
Probes whose difference between passages 3 and 7 was
less than the technical-variability cutoff were eliminated.
To filter probes by their biologic variability, a paired t
test was used between expression values at passage 3
and 7.
Probes were removed from the dataset if their P value
was greater than or equal to 0.05. For the magnitude of
expression filtering step, a background cutoff was cal-
culated from the mean and standard deviation of the A
signals from 2,489 negative controls and empty wells for
all the microarrays.
Probes whose mean A signals at passage 3 and 7 were
both less than the background cutoff (mean A signal
plus 1 standard deviation) were eliminated [43]. After fil-
tering, a repeated-measures ANOVA model using com-
pound symmetry correlation structure and pairwise
comparisons between passages was performed for each
probe (911 probes total) by using t statistics after accoun-
ting for the chosen variance-covariance structure. The
Cy3 expression value signal was added to each repeated-
measure ANOVA model as a covariate to account for
variability in the experimental units for each probe.
Multiplicity adjustment by using a P value threshold
of <0.001 (with a corresponding false discovery rate of
0.023 [44]) was also applied for all pairwise comparisons
between passages (911 probes × three pairwise compari-
sons = 2,733 P values). A Fisher Exact test was used by
Ingenuity Pathway Analysis (IPA) software to calculate
the range of P values for the each biofunction.
Cell-proliferation assay
The Click-iT EdU cell-proliferation assay (Life Technolo-
gies) was used to evaluate cell division per the manufac-
turer’s instructions. In brief, MSCs from four different
donors at passages 3 and 7 were plated on a 24-multiwell
dish at a density of 5,000 cells/cm2. Once adhered, cells
were mixed with the EdU reagent for both 6 and 18 hours.After the specified time in culture, MSCs were fixed and
stained with Alexa Fluor 488 for EdU detection. The cell
nuclei were visualized with Hoechst 33342 (Life Technolo-
gies) at a concentration of 5 μg/ml. Automated micros-
copy with a Nikon Ti-S inverted microscope with a 10×
objective was performed to acquire fluorescence images at
15 randomized locations per well. All MSC donors, pas-
sages, and time points were repeated in quadruplicate,
and CellProfiler version 2.0 was used to determine the
percentage of EdU-positive cells. A paired t test was used
to determine statistical differences in EdU expression of
MSCs between passages 3 and 7 at both 6 and 18 hours in
culture.
Results
Global microarray analysis of gene expression in MSCs
For gene-expression analysis, a randomized block design
for the two-color gene expression microarrays with a
reference was used to eliminate bias from microarrays
performed at different times (Additional file 1: Figure S1).
Linear and Lowess normalization rendered nearly iden-
tical normally distributed gene-expression signals (Log2
(Sample/Reference)) for all the arrays with a mean cen-
tered near zero (Figure 1B). This aided in eliminating bias
that may result at subsequent steps during the analysis
by ensuring that differences were due to passage and not
differences in signal range. An unsupervised principal-
component analysis of the six cell lines expanded to pas-
sage 7 was performed, and the percentage variance for the
first three principal components 1, 2, and 3, are 42.938,
33.348, and 23.714, respectively (Figure 1A). No single
principal component captured a majority of the variance,
indicating that no clear distinction exists between MSCs
from different donors or passages. Instead, some minor
clustering occurs among technical replicates. Further-
more, the technical variability per probe was very low,
with a mean range of 0.1483 to 0.2257 for all donors/pas-
sages (Figure 1C, green line).
Gene filtering
The objective of this study was to identify gene markers
indicating MSC aging in culture across all donors. This
provided the basis for the filtering process in which
probes exhibiting differences between passage 3 and 7
were more useful in terms of identification markers than
were differences observed between passages 3 and 5 or
passages 5 and 7. To identify probes with consistent up-
or downregulation with passage and therefore to mini-
mize the number of candidates, three robust filtering steps
were used: technical and biologic variability and their
magnitude of expression (Additional file 1: Figure S1).
The calculated difference in gene expression between
passages 3 and 7 for a single probe may be indistin-
guishable, based on the limitations of the microarray
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errors by determining a technical-variability cutoff per
probe. A technical-variability cutoff was calculated by
using standard deviations of the technical replicates
from 18 different samples.
Probes whose absolute mean difference between pas-
sages 3 and 7, not greater than this cutoff, were eli-
minated from the dataset, resulting in 6,219 probes
(Figure 2A).
Other investigators commonly choose an arbitrary fold-
change cutoff of 2 as a method to distinguish two condi-
tions as technical replication with microarrays, because
microarrays are costly [45,46]. Although this is generally a
good rule of thumb, it often necessitates verification by
real-time quantitative PCR to ensure the technical vari-
ability of the system using microarrays is not greater than
twofold itself.Figure 2 Gene filtration. (A) The mean difference between passage 7 an
34,555 probes. Blue probes (6,219) indicate that the differences between p
and used in further analysis, and black probes were below the cutoff and n
between passages 7 and 3 versus –Log10 (P value). Blue probes (1,713) ind
the biologic variability. (C) Distribution of the A signals of the background
of all the probes on the microarray. The blue spots represent the mean ge
red spots represent the mean gene expression and A signal at passage 3. T
1 standard deviation (μ + σ) are indicated by the red vertical lines.The other problem is that genes exhibiting a less than
twofold change may be of biologic value, but they are
often overlooked because of choosing an arbitrary cutoff.
Because each sample in these experiments was repeated
in triplicate, the technical variability can be calculated to
eliminate genes with low fold changes, but still have de-
tectable differences between two conditions (that is, pas-
sage 3 and 7 cells).
Biologic variability between MSCs from different do-
nors can have a major impact on the identification of
marker genes. Likewise, it is beneficial to eliminate genes
whose differences between passages 3 and 7 are highly
variable between donors, because the goal is to find
probes that can be used as reproducible gene markers.
These remaining probes were then filtered by their bio-
logic variability by means of a paired t test (α = 0.05) be-
tween passages 3 and 7. This eliminated probes in whichd passage 3 versus the technical-variability cutoff point per probe for
assages 7 and 3 are measurable. Blue probes were above the cutoff
ot used in further analysis. (B) Volcano plot of the mean difference
icate that the differences between passages 7 and 3 are greater than
spots with a mean and standard deviation of 9.042 ± 0.869. (D) MA plot
ne expression and A signal of the 911 probes at passage 7, and the
he mean of the background (μ) and the mean of the background plus
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and 7 of individual donors were highly variable, thus
resulting in 1,713 probes (Figure 2B).
To filter probes based on the magnitude of their
expression, the background A signal was calculated for
empty wells and negative controls, where the signal
should be zero. The background signal was normally
distributed, with a mean and standard deviation of
9.042 ± 0.869 (Figure 2C). Probes whose mean A signal
was not greater than the background cutoff at passage 3
or 7 were eliminated from the dataset. If the mean A
signal was greater than the background cutoff for only
one of the passages, then the probe was considered
expressed. The mean gene expression and A signal for
911 probes that passed each filtering step are visualized
on an MA (log of the ratio versus log of the mean) plot
for passages 3 and 7 (Figure 2D).
Identification of gene markers as a result of cell culture
The MSCs expressed the ISCT markers CD29+, CD44+,
CD73+, CD90+, CD105+, and CD166+ consistently
through cell passaging, with no statistically significant dif-
ferences observed [47]. With a repeated-measures ANOVA
with pairwise comparisons between passages and multipli-
city adjustment, the data resulted in 99 statistically signifi-
cant probes. In total, the 99 probes amounted to 81 genes
that were significantly different between passages 3 and 7,
where three genes are of an unknown classification
(Table 2). Significant changes were not observed for any of
the ISCT criteria markers; CD105+ (ENG), CD73+ (NT5E),
CD90+ (THY1), CD45- (PTPRC), CD34-, CD14-, CD11b-
(ITGAM), CD79α- (IGA), CD19- (B4), and HLA-DR,
nor other known classification markers, CD29+ (ITGB1),
CD166+ (ALCAM), and CD133- (PROM1). Four genes,
KRT18 (16), ITGBL1 (2), NTN4 (2), and RBPMS (2), were
spotted multiple times as different sequences across the
microarray and determined to be statistically significant. Of
the 78 known genes that were found to be significantly dif-
ferent, only one of the genes was not found to be significant
between passages 3 and 7, whereas only eight genes were
significantly different between passages 3 and 5, and three
genes were significantly different between passages 5 and 7
(Figure 3B). No genes were found to be statistically signifi-
cant between all combinations of passages.
In comparing gene expression between both vendors
Lonza and ALLCELLS at passage 3, no statistically sig-
nificant differences were found.
Hierarchic clustering by genes and passage revealed
the relative changes in expression from passages 3 to 7
of the 78 different known genes (Figure 3A). The expres-
sion profile of genes at passage 5 clustered more closely
with passage 7. Three clusters of genes exhibited upreg-
ulation from passages 3 to 7, whereas another three
clusters exhibited downregulation from passages 3 to 7.The top upregulated genes at passage 7 compared with
passage 3 were KRT18, NTN4, and BST1, with fold
changes of 3.62, 2.68, and 2.46, respectively (Table 2).
The top downregulated genes were PENK, COL12A1,
and BAALC, with fold changes of −4.15, −3.00, and −2.33,
respectively. The smallest fold changes detected for sta-
tistically significant genes were ATP5E, upregulated at
1.10, and AGK, downregulated at −1.10. A supervised
principal-component analysis of the 78 statistically signifi-
cant genes (represented by the 99 probes) between pas-
sages 3 and 7 reveals a clear separation between both
passages, with a majority of the percentage variance cap-
tured in the first principal component with 60.619%,
followed by 33.426% for principal component 2 and
5.955% for principal component 3 (Figure 3C). Principal
components 1 and 2 for the passage 3 donor samples clus-
ter closely with technical replicates; however, the distinct
separation indicates the biologic variability between do-
nors resulting from the identified genes. By passage 5,
samples represented by both the first two principal com-
ponents are intermixed with each other and samples at
passage 7; thus MSCs exhibit a greater similarity with
passaging.
IPA software was accessed on August 27, 2013, and
the 78 significant genes were uploaded to their database,
of which 74 genes were mapped. These were found to be
distributed throughout all compartments of the cell,
with 34.6% in the cytoplasm, 6.4% in the extracellular
space, 21.8% in the nucleus, 16.7% in the plasma mem-
brane, and 20.5% in an unknown location (Table 2). The
top molecular and cellular functions and physiological
system development and functions were predicted by
the IPA software (Table 3). A majority of the significant
genes were observed to have involvement in the categor-
ies of cellular development, cellular growth and prolifer-
ation, and tissue development.Comparison of gene-expression changes and cellular
proliferation
Because a majority of genes that were modulated as a re-
sult of cellular passage belonged to cellular growth and
proliferation, we performed cell-proliferation assays on
MSCs in passages 3 and 7. An EdU cell-proliferation
assay was used to evaluate differences in cell prolifera-
tion between passages 3 and 7 (Figure 4A). Despite the
variability in cell proliferation and percentage of cells
dividing between donors at a given passage, MSCs ex-
hibited a significantly greater potential for cell division
at passage 3, as more cells incorporated EdU in compari-
son to passage 7, at both time points (Figure 4B,C). The
fold changes in cellular proliferation between passages 3
and 7 were −1.62 and −1.42 when measured at 6 and 18
hours, respectively.












P7/P3 (Log2(MFC)) P5/P3 (Log2(MFC)) P7/P5 (Log2(MFC))
1 NM_003816 ADAM metallopeptidase domain 9 ADAM9 Plasma membrane 1.25 (0.321) NS NS 0.112 0.226
-
-
2 XM_005248381 ADAM 7metallopeptidase with
thrombospondin type 1 motif, 12
ADAMTS12 Unknown 1.59 (0.672) NS NS 0.143 0.477
-
-
3 NM_018238 Acylglycerol kinase AGK Cytoplasm −1.10 (−0.133) NS −1.13 (−0.170) 0.128 0.110
-
0.163
4 NM_001199183 ATPase, Ca2 transporting, type 2C,
member 1
ATP2C1 Cytoplasm 1.47 (0.555) NS NS 0.101 0.325
-
-
5 NM_006886 ATP synthase, H + transporting,
mitochondrial F1 complex, epsilon
subunit
ATP5E Cytoplasm 1.10 (0.142) 1.10 ([0.133) NS 0.092 0.069
0.084
-
6 NM_000489 Alpha thalassemia/mental retardation
syndrome X-linked
ATRX Nucleus 1.18 (0.242) NS NS 0.108 0.191
-
-
7 NM_024812 Brain and acute leukemia, cytoplasmic BAALC Cytoplasm −2.33 (−1.223) NS NS 0.105 0.509
-
-
8 NM_015379 Brain protein I3 BRI3 Unknown 1.26 (0.333) NS NS 0.112 0.237
-
-
9 NM_004334 Bone marrow stromal cell antigen 1 BST1 Plasma membrane 2.46 (1.297) NS NS 0.134 0.595
-
-

















Table 2 A list of statistically significant (P < 0.001) genes with indicated fold changes (Log2(fold change)) (Continued)
11 NM_174908 Coiled-coil domain containing 50 CCDC50 Cytoplasm 1.25 (0.322) NS NS 0.113 0.194
-
-
12 NM_003903 Cell division cycle 16 homolog
(Saccharomyces cerevisiae)
CDC16 Nucleus 1.16 (0.218) NS NS 0.093 0.059
-
-
13 NM_006319 CDP-diacylglycerol-inositol 3-
phosphatidyltransferase
CDIPT Cytoplasm 1.27 (0.345) NS NS 0.173 0.270
-
-
14 NM_001799 Cyclin-dependent kinase 7 CDK7 Nucleus 1.21 (0.278) NS NS 0.107 0.143
-
-
15 NM_001195132 Cyclin-dependent kinase inhibitor 2A
(melanoma, p16, inhibits CDK4)
CDKN2A Nucleus 1.37 (0.452) NS NS 0.104 0.402
-
-
16 NM_001854 Collagen, type XI, alpha 1 COL11A1 Extracellular space −2.19 (−1.132) NS NS 0.243 0.947
-
-
17 NM_004370 Collagen, type XII, alpha 1 COL12A1 Extracellular space −3.00 (−1.583) NS NS 0.185 0.895
-
-
18 NM_032609 Cytochrome c oxidase subunit IV
isoform 2 (lung)
COX4I2 Cytoplasm −1.33 (−0.407) NS NS 0.140 0.183
-
-
19 NM_000100 Cystatin B (stefin B) CSTB Cytoplasm 1.25 (0.323) NS NS 0.078 0.262
-
-
20 NG_021375 Discs, large homolog 2 (Drosophila) DLG2 Unknown 1.43 (0.521) NS NS 0.106 0.263
-
-
21 NM_025219 DNAJ (Hsp40) homolog, subfamily C,
member 5

















Table 2 A list of statistically significant (P < 0.001) genes with indicated fold changes (Log2(fold change)) (Continued)
22 NM_005740 Dynein, axonemal, light chain 4 DNAL4 Cytoplasm 1.54 (0.626) NS NS 0.138 0.335
-
-
23 NM_001009933 Deoxyribonuclease I-like 1 DNASE1L1 Cytoplasm 1.47 (0.559) NS NS 0.102 0.336
-
-
24 NM_033407 Dedicator of cytokinesis 7 DOCK7 Plasma membrane 1.29 (0.370) NS NS 0.116 0.249
-
-
25 NM_020390 Eukaryotic translation initiation factor
5A2







GALNT5 Cytoplasm 2.01 (1.005) 1.63 (0.705) NS 0.074 0.620
0.216
-
27 NM_001523 Hyaluronan synthase 1 HAS1 Plasma membrane −1.84 (−0.882) −1.42 (−0.507) NS 0.112 0.136
0.132
-
28 XM_005249437 Histone cluster 1, H2ac HIST1H2AC Unknown 1.99 (0.992) NS NS 0.159 0.904
-
-
29 NM_003535 Histone cluster 1, H3j HIST1H3J Nucleus −1.22 (−0.286) NS NS 0.136 0.200
-
-
30 NM_001130688 High-mobility group box 2 HMGB2 Nucleus −1.18 (−0.239) NS NS 0.082 0.135
-
-
31 XM_005266269 Heterogeneous nuclear
ribonucleoprotein A1-like 2
HNRNPA1L2 Unknown −1.47 (−0.557) NS NS 0.084 0.489
-
-
32 NM_004791 Integrin, beta-like 1 (with EGF-like repeat
domains)

















Table 2 A list of statistically significant (P < 0.001) genes with indicated fold changes (Log2(fold change)) (Continued)
33 NM_015167 Jumonji domain containing 6 JMJD6 Plasma membrane −1.16 (−0.220) NS NS 0.100 0.108
-
-
34 NG_028043 Kinesin family member 16B KIF16B Cytoplasm 2.04 (1.027) 1.62 (0.697) NS 0.094 0.547
0.175
-
35 NM_001300 Kruppel-like factor 6 KLF6 Nucleus −1.43 (−0.518) NS NS 0.148 0.086
-
36 NM_000223 Keratin 12 KRT12 Cytoplasm 1.51 (0.598) NS NS 0.234 0.377
-
37 NM_199187 Keratin 18 KRT18 a(16) Cytoplasm 3.62 (1.813) 2.34 (1.205) NS 0.157 0.891
0.497
-
38 NM_001080978 Leukocyte immunoglobulin-like
receptor, subfamily B (with TM and ITIM
domains), member 2
LILRB2 Plasma membrane 1.11 (0.156) NS NS 0.151 0.147
-
-
39 NM_144703 LSM14B, SCD6 homolog B
(Saccharomyces cerevisiae)
LSM14B Unknown −1.12 (−0.165) NS NS 0.116 0.118
-
-
40 NM_020152 MAP3K7 C-terminal like MAP3K7CL Unknown 2.36 (1.238) NS NS 0.13 0.962
-
-
41 NG_013325 Mitogen-activated protein kinase 10 MAPK10 Cytoplasm −1.15 (−0.201) −1.15 (−0.199) NS 0.146 0.172
0.196
-
42 NM_138799 Membrane bound O-acyltransferase
domain containing 2
MBOAT2 Cytoplasm −1.26 (−0.338) NS NS 0.105 0.279
-
-
43 NR_002766 Maternally expressed 3 (nonprotein
coding)

















Table 2 A list of statistically significant (P < 0.001) genes with indicated fold changes (Log2(fold change)) (Continued)
44 NM_001130156 Myeloid leukemia factor 1 MLF1 Nucleus −1.22 (−0.289) −1.19 (−0.256) NS 0.126 0.126
0.068
-
45 NM_170738 Mitochondrial ribosomal protein L11 MRPL11 Cytoplasm −1.17 (−0.230) NS NS 0.141 0.135
-
-
46 NM_002489 NADH dehydrogenase (ubiquinone) 1
alpha subcomplex, 4, 9 kDa
NDUFA4 Cytoplasm 1.25 (0.327) NS NS 0.107 0.257
-
-
47 NM_001018138 Nonmetastatic cells 2, protein (NM23B)
expressed in
NME2 Nucleus NS 1.13 (0.171) NS 0.099 -
0.156
-
48 NM_021229 Netrin 4 NTN4 a(2) Extracellular space 2.68 (1.401) NS NS 0.173 0.584
-
-
49 NM_000436 3-Oxoacid CoA transferase 1 OXCT1 Cytoplasm −1.29 (−0.365) NS NS 0.116 0.312
-
-
50 NM_182904 Prolyl 4-hydroxylase, alpha
polypeptide III
P4HA3 Unknown −1.19 (−0.250) NS NS 0.080 0.179
-
-
51 NM_006451 Poly(A) binding protein interacting
protein 1
PAIP1 Cytoplasm −1.22 (−0.284) NS NS 0.104 0.118
-
-
52 NM_006197 Pericentriolar material 1 PCM1 Cytoplasm −1.20 (−0.265) NS NS 0.138 0.172
-
-
53 NM_006211 Proenkephalin PENK Extracellular space −4.15 (−2.052) NS NS 0.161 0.915
-
-

















Table 2 A list of statistically significant (P < 0.001) genes with indicated fold changes (Log2(fold change)) (Continued)
55 NM_001172335 Plastin 3 PLS3 Cytoplasm 1.43 (0.515) NS NS 0.136 0.298
-
-
56 NM_006406 Peroxiredoxin 4 PRDX4 Cytoplasm 1.23 (0.301) NS NS 0.102 0.206
-
-
57 NM_182663 Ras association (RalGDS/AF-6) domain
family member 5
RASSF5 Plasma membrane 1.93 (0.947) NS NS 0.118 0.553
-
-
58 NM_006867 RNA-binding protein with multiple
splicing
RBPMS a(2) Unknown 1.23 (0.298) NS NS 0.111 0.111
-
-
59 NM_006802 Splicing factor 3a, subunit 3, 60 kDa SF3A3 Nucleus −1.26 (−0.333) NS NS 0.130 0.284
-
-
60 NM_003028 Src homology 2 domain containing
adaptor protein B
SHB Cytoplasm 1.33 (0.407) NS NS 0.118 0.203
-
-
61 NM_001142392 Solute carrier family 10 (sodium/bile
acid cotransporter family), member 3
SLC10A3 Plasma membrane 1.20 (0.261) NS NS 0.184 0.156
-
-
62 NM_005072 Solute carrier family 12 (potassium/
chloride transporters), member 4
SLC12A4 Plasma membrane 1.34 (0.424) NS NS 0.118 0.278
-
-
63 NM_005073 Solute carrier family 15 (oligopeptide
transporter), member 1
SLC15A1 Plasma membrane 1.17 (0.228) NS NS 0.201 0.109
-
-
64 NM_001166695 Solute carrier family 1 (glial high-affinity
glutamate transporter), member 3
SLC1A3 Plasma membrane −1.72 (−0.786) NS NS 0.183 0.352
-
-

















Table 2 A list of statistically significant (P < 0.001) genes with indicated fold changes (Log2(fold change)) (Continued)
66 NM_152313 Solute carrier family 36 (proton/amino
acid symporter), member 4
SLC36A4 Unknown −1.18 (−0.239) NS NS 0.124 0.156
-
-
67 NM_001013843 SAFB-like, transcription modulator SLTM Nucleus −1.15 (−0.196) NS NS 0.122 0.146
-
-
68 NM_003795 Sorting nexin 3 SNX3 Cytoplasm 1.22 (0.293) NS NS 0.126 0.279
-
-
69 NM_152343 Spermatogenesis associated 32 SPATA32 Unknown −1.17 (−0.229) NS NS 0.097 0.153
-
-
70 NM_004598 Sparc/osteonectin, cwcv and kazal-like
domains proteoglycan (testican) 1
SPOCK1 Extracellular space 2.07 (1.052) NS NS 0.148 0.729
-
-
71 NM_001159673 Synaptotagmin binding, cytoplasmic
RNA interacting protein
SYNCRIP Nucleus −1.24 (−0.312) NS −1.21 (−0.273) 0.100 0.139
-
0.169
72 NM_001006639 Transcription elongation factor A
(SII)-like 1
TCEAL1 Nucleus 1.23 (0.297) NS NS 0.099 0.090
-
-
73 NM_001006938 Transcription elongation factor A (SII)-
like 6
TCEAL6 Unknown 1.16 (0.218) NS NS 0.103 0.132
-
-
74 NM_031945 Tetraspanin 10 TSPAN10 Unknown 1.35 (0.435) NS NS 0.149 0.215
-
-
75 NM_001080415 U2 snRNP-associated SURP domain
containing
U2SURP Nucleus −1.17 (0.225) NS NS 0.105 0.196
-
-
76 NM_001167917 Ventricular zone-expressed PH domain
homolog 1 (zebrafish)

















Table 2 A list of statistically significant (P < 0.001) genes with indicated fold changes (Log2(fold change)) (Continued)
77 NM_006297 X-ray repair complementing defective
repair in Chinese hamster cells 1
XRCC1 Nucleus −1.14 (−0.190) NS NS 0.139 0.101
-
-
78 NM_015144 Zinc finger, CCHC domain containing 14 ZCCHC14 Unknown −1.18 (−0.235) NS NS 0.152 0.156
-
-
NS, not significant. aRepeated genes with different sequences (number of times), fold change, technical variability, and biologic variability (between each combination of passages), represented as the mean of















Figure 3 Identification of gene markers. (A) Hierarchic clustering heatmap of the 78 unique gene markers of passage. (B) Venn diagram of the
78 significantly different genes between each passage. (C) Supervised principal-component analysis based on the 99 significantly different probes
representing the 78 unique gene markers.
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Gene-expression profiling by microarray technology is an
excellent high-throughput method for profiling whole-genome expression of genes in any cell type and allows as-
sessment of changes in gene expression as cells are manip-
ulated in culture. We performed gene-expression profiling
Table 3 Ingenuity pathway analysis
Molecular and cellular functionsa
Function P value Number
of genes
Genes
Cell death and survival 1.33 × 10−4 –
4.52 × 10−2
15 ↑ATP2C1, ↑ATRX, ↑CDK7, ↑CDKN2A, ↑DNAJC5, ↓HMGB2, ↓KLF6, ↑KRT18, ↓MAPK10,
↑NTN4, ↓PENK, ↑PRDX4, ↑RASSF5, ↓SLC1A3, ↑SPOCK1
Cellular development 8.80 × 10−4 –
4.89 × 10−2
21 ↓AGK, ↑ATP2C1, ↑BST1, ↑CAV2, ↑CDC16, ↑CDKN2A, ↓COL11A1, ↑DOCK7, ↑EIF5A2,
↓HAS1, ↓HMGB2, ↓KLF6, ↑MEG3, ↑NME2*, ↑NTN4, ↓PCM1, ↓PENK, ↓PITX1, ↑RASSF5,
↑SLC12A4, ↓SLC1A3,
Cellular growth and proliferation 8.80 × 10−4 –
4.89 × 10−2
24 ↓AGK, ↑CAV2, ↑CDC16, ↑CDK7, ↑CDKN2A, ↑DOCK7, ↑EIF5A2, ↓HAS1, ↓HMGB2, ↓KLF6,
↑LILRB2, ↓MAPK10, ↑MEG3, ↑NME2*, ↑NTN4, ↓PENK, ↑PRDX4, ↑RASSF5, ↓SF3A3, ↑SHB,
↑SLC12A4, ↓SLC1A3, ↑SPOCK1, ↓XRCC1
Cell cycle 1.48 × 10−3 –
4.52 × 10−2
12 ↑ATRX, ↓AGK, ↑CDC16, ↑CDK7, ↑CDKN2A, ↓HAS1, ↓KLF6, ↑KRT18, ↓MLF1, ↓PCM1,
↑RASSF5, ↑SHB
Carbohydrate metabolism 3.85 × 10−3 –
2.82 × 10−2
5 ↓AGK, ↑CDIPT, ↑GALNT5, ↓HAS1, ↓SLC1A3,
Physiologic system development and function





1.48 × 10−3 –
1.91 × 10−2
3 ↑CAV2, ↑CDKN2A, ↓PCM1
Skeletal and muscular system
development and function
1.67 × 10−3 –
4.89 × 10−2
9 ↑CAV2, ↑CDKN2A, ↓COL11A1, ↓COL12A1, ↓COX4I2, ↑DNAJC5, ↓HMGB2, ↓PITX1,
↓SYNCRIP
Tissue development 1.67 × 10−3 –
4.89 × 10−2
16 ↑ADAM9, ↑ATP2C1, ↑CDKN2A, ↓COL11A1, ↓COL12A1, ↑CSTB, ↓HAS1, ↓HMGB2,
↓JMJD6, ↓KLF6, ↑KRT18, ↓MAPK10, ↑NME2*, ↑NTN4, ↓PITX1, ↓SLC1A3
Embryonic development 2.15 × 10−3 –
4.89 × 10−2
15 ↑ATP2C1, ↑CDK7, ↑CDKN2A, ↓COL12A1, ↑CSTB , ↑DNAJC5, ↓HMGB2, ↓KLF6, ↑KRT18,
↑NME2*, ↑NTN4, ↓PITX1, ↑SHB, ↓SLC1A3, ↓XRCC1
Organ development 2.15 × 10−3 –
4.89 × 10−2
13 ↑ADAM9, ↑ATP2C1, ↑CDKN2A, ↓COL12A1, ↑CSTB, ↑DNAJC5, ↓HMGB2, ↓KLF6, ↑KRT18,
↑NME2*, ↑NTN4, ↓PITX1, ↓SLC1A3
List of genes (up- or downregulated) involved in top functions. Fisher Exact Test was used by IPA to calculate the range of P values. ↑upregulated,
↓downregulated, *Not significant between passages 3 and 7.
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saged in cell culture. By highly robust statistical analysis,
we discovered that 99 statistically significant probes chan-
ged expression as a result of time in cell culture. These 99
probes represented 81 unique genes that were significantly
different between at least two different passages, of which
78 are known, and three have not been classified. We
previously reported that these MSCs showed similar phe-
notypes at passages 3 and 7, despite gene-expression
changes. In addition, MSCs from two different vendors
exhibited uniform changes in gene expression.
For gene markers that can accurately indicate quality
of MSCs in culture, markers should show a consistent
pattern over time, such as an up- or downregulation, in
comparison with an early time point. Genes with a tem-
poral change in expression where expression at P5 is sig-
nificantly different with P3; however, expression between
P3 and P7 is not significant, and would not make an
ideal gene marker. Instead, a gene marker with a signifi-
cant difference between P3 and P7 would be a better
predictor of MSC quality. Our filtering methods ensured
that sensitivity issues (Figure 3A) and donor variation
(Figure 3B) would not obscure results by eliminating
genes from the dataset where expression differencesbetween passage 3 and 7 were highly variable and not
reproducible.
Combined with our multiplicity adjustment methods,
we were also able to exclude genes whose statistical sig-
nificance was likely due to chance. With these analytic
techniques, we identified three clusters of genes that ex-
hibited upregulation from passages 3 to 7, whereas an-
other three clusters exhibited downregulation from
passages 3 to 7.
Previous investigations have executed similar studies
involving gene-expression profiling of human MSCs de-
rived from bone marrow with long-term culture. Kul-
terer et al. reported that 838 genes were differentially
expressed between P2 and P5, with 10 of those genes
matching those identified in our study (Table 2) (BST1,
COL11A1, COL12A1, GALNT5, HAS1, KRT18, MEG3,
PCM1, PENK, and SHB) [48]. Likewise, in another study
by Tanabe et al., two genes reported matched those
found in our study (KRT18 and PRDX4) [49]. A number
of reasons exist for the discrepancies from a biologic
standpoint, including culture conditions, media used, and
the source of MSCs; however, poor experimental design
and statistical analysis are the primary sources for mis-
leading results. Ren et al. [50] examined the effects of cell
Figure 4 Analysis of MSC proliferation at passages 3 and 7. (A) The percentage of EdU-positive cells was determined for four different
donors after both 6 and 18 hours at passages 3 and 7 (EdU, green;, nuclei, blue). (B) A paired t test indicated a statistically significant difference
(P < 0.05) between passages 3 and 7 for EdU-positive expression at 6 hours. (C) A paired t test indicated a statistically significant difference
between passages 3 and 7 for EdU-positive expression at 18 hours.
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degree of senescence in contrast to passage. This study
used a highly robust statistical analysis, which identified
15 statistically significant genes (ADAMTS12, BAALC,
BST1, CAV2, CDKN2A, COL11A1, COL12A1, DNASE1L1,
EIF5A2, GALNT5, KRT18, MEG3, NTN4, SLC1A3, and
VEPH1) that were identical to our gene list with the same
up-/downregulation compared with early passages. The
magnitude of fold change was also typically greater than
the magnitude of fold change reported in our own results,
and this may be due to Ren et al. carrying out cell cultures
to a higher passage number. This suggests that minute dif-
ferences in gene expression detected between closely re-
lated passages increases with more-distant passages or
cellular aging.Approximately 37% of the 78 gene markers imported
into IPA were observed to have some function related to
cellular growth and proliferation and cellular develop-
ment. Two of the 78 different marker genes belong to
the keratin family, KRT12 and KRT18, in which signifi-
cant gene-expression changes were observed in multiple
publications [48-50]. Keratins are fibrous structural pro-
teins that play a major functional role in the integrity
and mechanical stability of epithelial tissues [51]. Typic-
ally, keratins are observed in pairs such as KRT18 and
KRT8, which are co-expressed in simple epithelium. As
indicated in IPA (Table 3), keratins are strongly connected
to the functions of cell cycle and cell death and survival,
which can profoundly affect cellular development. In-
creases in keratin expression are particularly observed
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or in organs such as the pancreas or liver [52-56]. Sixteen
different sequences representing the KRT18 gene on these
microarray chips were upregulated at passage 7 compared
with passage 3. KRT18 expression has also been suggested
to play a role in the immunosuppressive potential of graft-
versus-host disease (GVHD). KRT18 expression, as mea-
sured by serum fragments, was found to be elevated in
lower gastrointestinal tract and liver GVHD [57,58]. Im-
munosuppressive therapy for GVHD resulted in decreases
of KRT18 serum fragments.
Like KRT18, NTN4, a laminin-related secreted mol-
ecule protein exhibited more than a twofold upregula-
tion in gene expression from passages 3 to 7. Studies
suggests that NTN4 expression is tied to decreases in
cell proliferation, as has been observed in corneal and
pancreatic epithelium, as well as in a human breast can-
cer cell line (MCF7) [59-61]. However, conflicting argu-
ments have been made about the function of NTN4, as
it has been observed to promote cell proliferation in
various tumor cell types [62-64]. Similarly, BST1, bone
marrow stromal cell antigen 1, was observed to have a
2.46-fold change from passages 3 to 7. It is a stromal cell
line-derived glycosylphosphatidylinositol-anchored mol-
ecule that has been identified to facilitate pre-B-cell mat-
uration based on its enhanced expression in rheumatoid
arthritis-derived bone marrow stromal cell lines and ac-
tivation by Pax5 [65-67]. An increase in BST1 expression
has been observed in several studies with aging in cul-
ture, in which elevated expression levels have been tied
to nonneurogenesis-promoting astrocytes [48,68,69].
The gene that exhibited the greatest change in ex-
pression from passages 3 to 7 was PENK, which was
downregulated 4.15 fold. PENK is an endogenous opioid
polypeptide hormone found at high levels in the brain
and endocrine tissues [70]. They typically function as
neurotransmitters to modulate pain, cellular growth, or-
ganogenesis, and immunity, because they are also widely
observed in nonneuronal tissues [71]. PENK expression,
known in early neuronal development, was observed to be
upregulated in neuron-like differentiated bone marrow-
derived MSCs compared with undifferentiated MSCs [72].
Likewise, SYNCRIP, which was downregulated from pas-
sages 3 to 7 by 1.24 fold, has been involved in neuronal
synaptic transmission and was also exhibited to be upreg-
ulated in neurogenic differentiated MSCs. PENK expres-
sion has also been linked to osteoblastic development, in
which decreases in PENK paralleled decreases in osteo-
genic differentiation, as measured alkaline phosphatase ac-
tivity [73,74]. A later study has indicated that may not be
true for in vivo experiments as PENK-deficient mice did
not exhibit a difference in bone remodeling compared
with wild-type littermates unless PENK expression was
deleted from Phex-deficient Hyp mice [75].Another gene typically involved with the developing
central and peripheral nervous systems expressed to en-
hance growth is KLF6 [76]. KLF6 is known as a zinc-
finger DNA-binding transcription factor regulating gene
expression and was downregulated from passages 3 to 7
by −1.43. Two different studies examining KLF6 in mice
found that their expression affects neuronal morphogen-
esis by promoting axon outgrowth [77,78]. Furthermore,
KLF6 expression was observed to regulate proliferation
and differentiation positively as KLF6−/− ES cells dem-
onstrated significant defects after differentiation into
embryoid bodies.
Like PENK, BAALC exhibited a 2.33-fold downregula-
tion from passages 3 to 7. BAALC is an overexpressed
gene usually found in a subset of patients with acute
myeloid leukemia within neuroectoderm-derived and
mesoderm tissues [79,80]. Its expression has also been
observed in early hematopoietic progenitor cells, in which
its subsequent loss is associated with cell differentiation
[81]. Because the expression of BAALC was dramatically
reduced with increasing passage, this suggests the MSCs
lose their multipotent potential as they aged in culture.
Two genes associated with fibril elongation, COL11A1
and COL12A1, were also observed to be downregulated
with increasing passage more than twofold. Elevated levels
of expression are observed for both genes in response to
different cell-proliferative assays. In hyalocytes, ascorbic
acid was observed to increase their proliferation in com-
bination with increasing COL11A1 expression, whereas in
a different study, chondrocytes exhibited high-density
micromass growth in conjunction with COL11A1 [82,83].
Similarly, COL12A1 was upregulated with the growth of
glioblastoma multiforme compared with normal brain,
and when the proliferative potential of SKOV3 cells was
reduced by knocking down the expression of RUNX1,
COL12A1 expression also decreased [84,85]. Other studies
have also indicated that an elevated level of expression
leads to osteoblast differentiation and maturation, whereas
their suppression can terminate this process [86-88]. In
our study, the decrease in both collagens with passaging
suggests a reduced capacity for osteogenic differentiation
or limited MSC multipotency.
The gene markers presented in this study allude to
MSC senescence and unwanted differentiation that can
often go unnoticed with passage. Multiple studies have
demonstrated that MSCs exhibit a reduction in cellu-
lar proliferation with culture, which is consistent with
our current work when these identical donors were
evaluated [35,39,89]. Our previous studies examining
these same donors exhibited increases in cell size with
length in culture by flow cytometry and automated cell
counting [39,47].
Furthermore, our prior work investigating the multipo-
tency of these MSCs illustrated a decreased percentage of
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genic differentiation, as observed by the percentage of
Nile red-positive cells [39,47]. Rather than using bio-
assays to determine MSC quality during passaging
and cell expansion, future work may establish quality
through the expression of a set of gene or protein mar-
kers. Based on these results, MSCs performance is most
likely best at earlier passages of culturing. The conglo-
merate of these gene markers exhibiting altered gene
expression at passage 7 suggests that they are under-
going terminal differentiation that is comparable with
reaching cellular senescence. This can negatively af-
fect potential therapeutic applications in which the
transplantation of aged cells can send detrimental sig-
nals leading to erroneous regeneration or prevent im-
munosuppression. Extreme caution should be considered
when using the ISCT markers for MSC characteri-
zation, as they are commonly used as quality markers
when generating criteria for lot release with respect
to MSC identity and purity [90]. Despite the use of
ISCT markers to establish purity of an MSC popula-
tion, heterogeneity and diminished performance per-
sist with continuous culturing, whereas ISCT marker
expression remains consistent [47]. Our prior and current
results indicate significant changes in MSC performance
through biologic assays and gene expression; thus the
identified gene markers may be useful in producing qual-
ity markers of cellular aging over successive rounds of
passaging.
Additional work is necessary to determine whether the
expression of identified gene markers is consistently
modulated when cellular expansion is scaled up by using
bioreactors or performed with different substrates and
media components. Discovering genes expressed in
MSCs that correlate with a functional outcome will pro-
vide a basis for a set of quality markers. These quality
markers can then be used to assess cellular products de-
sired for a specific application. These are major consid-
erations in establishing quality, function, and safety of
MSCs for therapeutic purposes.Conclusions
An increasing interest exists in determining markers that
can be used to distinguish between different donors and
culture conditions of MSCs. As MSCs are aged in cul-
ture, they begin to exhibit gene-expression changes re-
lated to cell growth and proliferation, cell survival, and
cellular development as observed through reduced cellu-
lar proliferation at a higher passage. Reproducible gene-
expression changes were consistently detected among
different MSC donors. Results obtained from these stud-
ies may provide insights into MSC differentiation and
function with passaging in culture.Additional file
Additional file 1: Figure S1. Outline of the major topics and
interrelated steps used to analyze microarray data. (1) Experimental
design, (2) normalization, (3) gene filter, (4) statistical analysis, and (5)
pathway analysis.
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